For the 365 million individuals in the world suffering from hyperhidrosis (excessive sweating), the condition has resulted in occupational, emotional, psychological, social, and physical impairment. In addition, hyperhidrosis is undertreated and underrecognized as a serious disorder negatively impacting the quality of life for both adults and adolescents. According to the American Academy of Dermatology, half of people with hyperhidrosis delay treatment for 10 years or more.
With limited treatments available for hyperhidrosis patients, clinical-stage company Brickell Biotech has been developing a new potential non-invasive treatment focused on axillary hyperhidrosis (excessive underarm sweating). Clinically Media was retained to develop a comprehensive Central Campaign to recruit and enroll two parallel US-based Phase III trials efficiently with qualified adult and pediatric patients.
Additional Challenges Faced
Clinically Media's Solution
Through advanced IT support and customized solutions, Clinically Media was able to develop a cohesive brand, streamline lead generation, and lessen the burden placed on research sites. As a result, Clinically Media successfully enrolled the study in the anticipated 7-month enrollment period.